NeuroPace, Inc.

71 articles about NeuroPace, Inc.

• NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference

  9/20/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023, at 1:15 p.m. ET in New York, New York.

• NeuroPace to Participate in Upcoming September 2023 Investor Conferences

  8/24/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, announced its participation in the following upcoming investor conferences:

• NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

  8/8/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the second quarter ended June 30, 2023.

• NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market - July 19, 2023

  7/19/2023

  NeuroPace, Inc. announced that it granted to Joel Becker, NeuroPace’s recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace’s common stock at an exercise price of $4.39 under its 2023 Inducement Plan.

• NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023

  7/18/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2023 after market close on Tuesday August 8, 2023.

• NeuroPace Announces CEO Transition

  6/28/2023

  NeuroPace, Inc. announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023.

• NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales

  5/24/2023

  NeuroPace, Inc. announced the appointment of Ms. Kelley Nicholas as Vice President of Sales effective May 22, 2023.

• NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance

  5/4/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the first quarter ended March 31, 2023.

• NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023

  4/17/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023.

• NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference

  4/3/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference.

• NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results

  3/2/2023

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the fourth quarter and full-year ended December 31, 2022.

• NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

  2/10/2023

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 2, 2023.

• NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors

  1/9/2023

  NeuroPace, Inc. announced preliminary, unaudited revenue results for the fourth quarter and full-year ended December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors.

• NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference

  12/21/2022

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

• NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway

  11/30/2022

  NeuroPace, Inc today announced that the first patient with Lennox-Gastaut Syndrome (LGS) was treated in its feasibility investigational device exemption (IDE) study.

• NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update

  11/8/2022

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022.

• NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference

  11/4/2022

  NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, announced it will be participating in the upcoming 4th Annual Wolfe Research Healthcare Conference.

• NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022

  10/25/2022

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8, 2022.

• NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

  10/11/2022

  NeuroPace, Inc today announced the first patient implanted in the NAUTILUS clinical study.

• NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference      

  8/23/2022

  NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference.